Reversing endothelial dysfunction with empagliflozin to improve cardiomyocyte function in cardiorenal syndrome
Open Access
- 1 May 2021
- journal article
- editorial
- Published by Elsevier BV in Kidney International
- Vol. 99 (5), 1062-1064
- https://doi.org/10.1016/j.kint.2021.01.008
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Empagliflozin restores chronic kidney disease–induced impairment of endothelial regulation of cardiomyocyte relaxation and contractionKidney International, 2020
- Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes—Systematic review and meta-analysis of randomized placebo-controlled trialsAmerican Heart Journal, 2020
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureThe New England Journal of Medicine, 2020
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionThe New England Journal of Medicine, 2019
- Endothelial Toxicity of High Glucose and its by-Products in Diabetic Kidney DiseaseToxins, 2019
- Cardiac Microvascular Endothelial Enhancement of Cardiomyocyte Function Is Impaired by Inflammation and Restored by EmpagliflozinJACC: Basic To Translational Science, 2019
- Endothelium structure and function in kidney health and diseaseNature Reviews Nephrology, 2019
- Cardiotoxicity of Uremic Toxins: A Driver of Cardiorenal SyndromeToxins, 2018
- SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art reviewDiabetologia, 2018